Rathbones Group PLC bought a new stake in shares of Mesoblast Limited (NASDAQ:MESO – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,017 shares of the company’s stock, valued at approximately $95,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after purchasing an additional 1,663 shares during the period. Perkins Coie Trust Co bought a new position in Mesoblast in the second quarter valued at about $68,000. Pine Valley Investments Ltd Liability Co bought a new position in Mesoblast in the second quarter valued at about $80,000. Chapin Davis Inc. raised its stake in shares of Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after buying an additional 5,000 shares during the period. Finally, Chase Investment Counsel Corp bought a new position in shares of Mesoblast in the first quarter worth about $298,000. Institutional investors own 1.43% of the company’s stock.
Mesoblast Stock Performance
MESO opened at $6.10 on Wednesday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $696.49 million, a PE ratio of -5.44 and a beta of 3.47. The firm’s 50-day moving average price is $6.72 and its 200 day moving average price is $6.20. Mesoblast Limited has a twelve month low of $1.61 and a twelve month high of $8.66.
Analysts Set New Price Targets
Check Out Our Latest Report on Mesoblast
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
- Five stocks we like better than Mesoblast
- What is an Earnings Surprise?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Best Stocks Under $5.00
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- 3 Warren Buffett Stocks to Buy Now
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.